- Home
- AMRN
as 06-25-2025 11:30am EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 216.0M | IPO Year: | 1993 |
| Target Price: | $7.00 | AVG Volume (30 days): | 152.6K |
| Analyst Decision: | Strong Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.08 - $17.18 | Next Earning Date: | 07-30-2025 |
| Revenue: | $214,112,000 | Revenue Growth: | -22.83% |
| Revenue Growth (this year): | -21.07% | Revenue Growth (next year): | 7.88% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
MT Newswires
20 hours ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
a day ago
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT Newswires
a day ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires
a day ago
Update: Amarin Signs Licensing Deal With Recordati for Vazkepa in Europe; Shares Rise
MT Newswires
a day ago
Amarin Signs Licensing Deal With Recordati for Vazkepa in Europe
GlobeNewswire
a day ago
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
GlobeNewswire
a day ago
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
Zacks
6 days ago
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.